Stocks · News reference
Glucotrack Subsidiary Lōkahi Therapeutics Engaged Two ai² PIPELINE Project Teams To Identify And Evaluate Brain Tumor Therapeutic Assets Available For Licensing And Development
Innovate GBM becomes the first external organization to engage the ai² Division on a fee-for-service basis to identify brain tumor therapeutic assets for potential licensing and developmentLōkahi Therapeutics™ Inc., a
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Glucotrack's Lōkahi Therapeutics Announces Partnership With Pepperdine Business School For MBA Students To Evaluate Drug Assets
8-K filing — Glucotrack, Inc. (GCTK)
Filed: 2026-09-24 AccNo: 0001493152-26-044182 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
What's Going On With GlucoTrack Shares On Thursday?
GlucoTrack subsidiary Lokahi Therapeutics secured its first external fee-for-service partnership with nonprofit Innovate GBM for glioblastoma research.